FDA Inspection
Onyx Pharmaceuticals, Inc., a Subsidiary of Amgen, Inc.Onyx Pharmaceuticals, Inc., a Subsidiary of Amgen, Inc. – FDA Inspection, Jan 20, 2012
Record Details
This FDA Inspection record concerns Onyx Pharmaceuticals, Inc., a Subsidiary of Amgen, Inc., with an inspection on January 20, 2012, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- January 20, 2012
- Product Type
- Drugs
View Company Profile
ID · 1a73ad03-4282-4023-aab8-00cb7d7d3c5b
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 765467
- FDA center
- Human Drugs
- Project area
- Bioresearch Monitoring
FDA Citations
2- 21 CFR 312.50Ensuring compliance with plan and protocol
- 21 CFR 312.50General responsibilities of sponsors
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Onyx Pharmaceuticals, Inc., a Subsidiary of Amgen, Inc.
2| Date | Classification | Office | Project area |
|---|---|---|---|
| February 6, 2015 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 17, 2013 | VAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Onyx Pharmaceuticals, Inc., a Subsidiary of Amgen, Inc.
- FDA Inspection 914497 - 2015-02-06
- FDA Inspection 833837 - 2013-05-17
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.